Burning rock announces the launch of china's first prospective pan-cancer multi-omics early detection study

Beijing, may 19, 2021 (globe newswire) -- burning rock biotech limited (nasdaq: bnr, the “company” or “burning rock”) today announced the launch of the prescient (pan-cancer early-stage detection by liquid biopsy technique project) study, the first blood-based, pan-cancer early-detection study in china using a multi-omics approach. the study is going to be led by professor jie he, fellow of the chinese academy of sciences and head of the china national cancer center, and professor jie wang. both are residing physicians at the national cancer center and the cancer hospital of the chinese academy of medical sciences.
BNR Ratings Summary
BNR Quant Ranking